Drug Treatment for Alcoholics With Bipolar Disorder
Launched by NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA) · Nov 2, 1999
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
The aim of this study is to test the mood stabilizer, anticonvulsant, sodium valproate in individuals with alcohol dependence and bipolar disorder, in a double-blind, placebo-controlled, and randomized trial of 6 months duration. All subjects are treated with treatment as usual, which include lithium carbonate and individual dual recovery counseling and are randomized to either sodium valproate or placebo.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Meets the criteria for alcohol dependence with comorbid bipolar disorder.
- • Agreement to participate in outpatient treatment.
- • Ability to tolerate lithium carbonate and be randomized to receive sodium valproate or placebo.
- • Stable living situation.
- • Ability to provide informed consent.
- Exclusion Criteria:
- • Psychiatric conditions including schizophrenia, schizoaffective disorder, any non-bipolar psychotic disorder, unipolar major depression, mental retardation, or signs of impaired cognitive functioning.
- • Neurological conditions including epilepsy, history of brain injury, encephalitis, or any organic brain syndrome or focally abnormal electroencephalographic examination.
- • Medical conditions including severe cardiac, liver, kidney, endocrine, hematologic, other impairing or unstable medical condition or impending surgery.
- • Persistent elevation of liver function enzymes indicating active liver disease.
- • Pregnancy or not using an acceptable contraceptive method.
- • Inability to read or understand study forms; agree to informed consent.
- • Impending incarceration or a mandate to attend treatment by the legal system for an alcohol use disorder.
- • The presence of either/or cocaine dependence, opioid dependence, and intravenous drug use.
About National Institute On Alcohol Abuse And Alcoholism (Niaaa)
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is a leading federal agency dedicated to advancing research on alcohol-related health issues and fostering a deeper understanding of alcohol use disorders. As part of the National Institutes of Health (NIH), NIAAA supports a diverse portfolio of clinical trials aimed at developing innovative prevention and treatment strategies for alcohol abuse and dependence. By collaborating with researchers, healthcare providers, and community organizations, NIAAA strives to translate scientific findings into effective public health initiatives, ultimately aiming to reduce the impact of alcohol on individuals and society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Ihsan M Salloum, MD, MPH
Principal Investigator
University of Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials